Comparative cost-effectiveness of a fluticasone propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 13-22

  Dalal, Anand A ^a   Roberts, Melissa H ^b   Petersen, Hans V ^b   Blanchette, Christopher M ^c   Mapel, Douglas W ^a  

^a GLAXOSMITHKLINE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c Lovelace Clinic Foundation ^*

Author keywords

Advair ; Chronic obstructive pulmonary disease; Costs; Ipratropium; Tiotropium; Utilization

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; TIOTROPIUM BROMIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTPATIENT CARE; RETROSPECTIVE STUDY; RISK ASSESSMENT; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG UTILIZATION; HEALTH CARE UTILIZATION; HEALTH INSURANCE; RISK REDUCTION;

AGED; ALBUTEROL; AMBULATORY CARE; ANDROSTADIENES; CHOLINERGIC ANTAGONISTS; COST-BENEFIT ANALYSIS; DRUG COMBINATIONS; DRUG COSTS; DRUG PRESCRIPTIONS; EMERGENCY MEDICAL SERVICES; FEMALE; GLUCOCORTICOIDS; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; IPRATROPIUM; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MODELS, ECONOMIC; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCOPOLAMINE DERIVATIVES; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 79251501662     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S15455     Document Type: Article

References (18)

1. American Lung Association. Chronic Obstructive Pulmonary disease (COPD) Fact Sheet. Washington, DC: American Lung Association, 2009. Available at: www.lungusa.org/lung-disease/copd/resources/facts-figures/COPD-Fact-Sheet.html#note_08. Accessed 2010 Nov 12.
2. National Heart, Lung and Blood Institute. Morbidity and Mortality: 2007 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: U.S. Department of Health and Human Services; 2007.
3. Celli BR, MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD. Gig Harbor, WA: Medical Communications Resources, Inc; 2009 Dec.
5. Akazawa M, Hayflinger DC, Stanford RH, Blanchette CM. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care. 2008;14:438-448.
6. Anzueto A, McLaughlin T, Stanford RH. Initial treatment regimen and risk of hospitalization in patients with chronic obstructive pulmonary disease. COPD. 2004;1:205-214.
7. Blanchette CM, Akazawa M, Dalal A, Simoni-Wastila L. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 μg /salmeterol 50 μg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Am J Geriatr Pharmacother. 2008;6:138-146.
8. Dalal AA, Petersen H, Simoni-Wastila L, Blanchette CM. Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD. J Med Econ. 2009;12:339-347.
9. Delea TE, Hagiwara M, Dalal AA, Stanford RH, Blanchette CM. Healthcare use and costs in patients with chronic bronchitis initiating maintenance therapy with fluticasone/salmeterol vs other inhaled maintenance therapies. Curr Med Res Opin. 2009;25:1-13.
10. Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther. 2005;27:346-354.
11. Rascati KL, Akazawa M, Johnsrud M, Stanford RH, Blanchette CM. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther. 2007;29:1203-1213.
12. Oostenbrink JB, Rutten-van Mölken MP, Al MJ, van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004;23:241-249.
13. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/ fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.
14. Tukey JW. Exploratory Data Analysis. 1st ed. Reading, MA: Addison-Wesley Publishing Company; 1977.
15. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
16. Dalal AA, Blanchette CM, Roberts MH, Petersen HV, Mapel DW. Healthcare utilization and direct medical costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus tiotropium in elderly, Medicare-eligible patients with COPD. J Med Econ. 2010 Sep 20. [Epub ahead of print].
17. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic obstructive pulmonary disease. Respir Med. 2005;99:1325-1333.
18. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Pract. 2009;63:1136-1149.